{"preliminary_commentary":{"by_channel":{"x_thread":4},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"NCT03113643","nct_id":"NCT03113643","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct03113643. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"SL-401 will be administered every 4 weeks, on a 28 day cycle; SL-401 will be given intravenously; Azacitidine will be administered every 4 weeks, on a 28 day cycle; Azacitidine will be given intravenously or subcutaneously","label":"SL-401+ Azacitidine","type":"EXPERIMENTAL"},{"description":"SL-401 will be administered every 4 weeks, on a 28 day cycle; SL-401 will be given intravenously; Azacitidine will be administered every 4 weeks, on a 28 day cycle; Azacitidine will be given intravenously or subcutaneously; Venetoclax will be administered for 21 days on a 28 day cycle; Venetoclax will be taken orally","label":"SL-401+ Azacitidine + Venetoclax","type":"EXPERIMENTAL"}],"collaborators":["Stemline Therapeutics, Inc."],"completion_date":{"date":"2027-05-31","type":"ESTIMATED"},"conditions":["Acute Myeloid Leukemia","Myelodysplastic Syndrome","Blastic Plasmacytoid Dendritic Cell Neoplasm"],"enrollment":{"count":72,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Azacitidine","otherNames":["Vidaza"],"type":"DRUG"},{"name":"SL-401","otherNames":[],"type":"DRUG"},{"name":"Venetoclax","otherNames":["Venclyxto, Venclexta"],"type":"DRUG"}],"last_update":"2026-06-17","lead_sponsor":"Dana-Farber Cancer Institute","official_title":"Phase 1 Study of SL-401 in Combination With Azacitidine and Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Treatment-Naive Subjects With AML Not Eligible for Standard Induction and in Subjects With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) or SL-401 in Combination With Azacitidine in Subjects With High-Risk Myelodysplastic Syndrome (MDS)","overall_status":"RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2021-09-15","type":"ACTUAL"},"primary_outcomes":[{"measure":"Maximum Tolerated Dose","timeFrame":"2 years"}],"references":[{"citation":"Lane AA, Luskin MR, Keating J, LeBoeuf NR, Garcia JS, Shimony S, Leonard R, Goodpaster A, Nguyen TT, Galinsky I, Eberly-Puleo A, Daver N, Jain N, Garcia-Manero G, Kantarjian H, Konopleva MY, Stein A, Pemmaraju N. Tagraxofusp, azacitidine, and venetoclax for blastic plasmacytoid dendritic cell neoplasm. Blood. 2026 Oct 29;148(18):2229-2238. doi: 10.1182/blood.2026033906.","pmid":"42413008","type":"DERIVED"},{"citation":"Lane AA, Garcia JS, Raulston EG, Garzon JL, Galinsky I, Baxter EW, Leonard R, DeAngelo DJ, Luskin MR, Reilly CR, Stahl M, Stone RM, Vedula RS, Wadleigh MM, Winer ES, Mughal T, Brooks C, Gupta IV, Stevenson KE, Neuberg DS, Ren S, Keating J, Konopleva M, Stein A, Pemmaraju N. Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia. Blood Adv. 2024 Feb 13;8(3):591-602. doi: 10.1182/bloodadvances.2023011721.","pmid":"38052038","type":"DERIVED"},{"citation":"Wang SY, Thomassen K, Kurch L, Opitz S, Franke GN, Bach E, Platzbecker U, Kayser S. Combination of Tagraxofusp and Azacitidine Is an Effective Option for Relapsed Blastic Plasmacytoid Dendritic Cell Neoplasm After Allogeneic Hematopoietic Stem-Cell Transplantation. Clin Lymphoma Myeloma Leuk. 2021 Jul;21(7):e579-e582. doi: 10.1016/j.clml.2021.02.008. Epub 2021 Mar 2. No abstract available.","pmid":"33795208","type":"DERIVED"}],"start_date":{"date":"2017-06-26","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)","url":"https://clinicaltrials.gov/study/NCT03113643"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct03113643"}